| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2018/010 | ||
|---|---|---|---|
| Date of filing | 09/02/2018 | ||
| Notification of Application Published | 07/03/2018 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
Merck Serono S.A. Centre Industriel 1267 Coinsins Vaud SWITZERLAND |
||
| Patent Number | 1827461 | ||
| Title of Invention | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS | ||
| Date of Expiry of Patent | 19/12/2025 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Cladribine | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/17/1212 | ||
| Authorisation Date | 24/08/2017 | ||
| Identity of Product Authorised | MAVENCLAD - cladribine | ||
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||
| Renewal Fees | |||
| 14/02/2018 | Request for grant a Supplementary Protection Certificate filed on 09/02/2018, numbered 2018/010. | ||
| 08/09/2025 | Request for grant of Supplementary Protection Certification No. 2018/010 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||